Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
T.C. Martinsen, K. Bergh, H.L. Waldum.
Gastric juice: a barrier against infectious diseases.
Basic Clin Pharm Toxicol, 96 (2005), pp. 94-102
[2.]
F.W. Green Jr, M.M. Kaplan, L.E. Curtis, P.H. Levine.
Effect of acid and pepsin pn blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage.
Gastroenterology, 74 (1978), pp. 38-43
[3.]
G.I. Leontiadis, V.K. Sharma, C.W. Howden.
Proton pump inhibitor treatment for acute peptic ulcer bleeding.
Cochrane Database Syst Rev, (2006),
[4.]
Información terapéutica.
SNS, 33 (2009), pp. 120-121
[5.]
Q.D. Pham, R.E. Regal, T.R. Bostwick, K.S. Knauf.
Acid suppresive therapy use on an inpatient internal medicine service.
Ann Pharmacother, 40 (2006), pp. 1261-1266
[6.]
J. Labenz, K.U. Petersen, W. Rösch, H.R. Koelz.
A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole.
Aliment Pharmacol Ther, 17 (2003), pp. 1015-1019
[7.]
J.V. Esplugues, M. Marti-Cabrera, J. Ponce.
Safety of proton pump inhibitors.
Med Clin (Barc), 127 (2006), pp. 790-795
[8.]
U. Mahadevan, S. Kane.
American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy.
Gastroenterology, 131 (2006), pp. 278-282
[9.]
A. Lanas.
Inhibidores de la bomba de protones y clopidogrel en el paciente cardiovascular: ¿riesgo cardiovascular versus riesgo gastrointestinal?.
Gastroenterol Hepatol, 33 (2010), pp. 1-5
Copyright © 2010. Elsevier España S.L.. Todos los derechos reservados
